Protalix Biotherapeutics Stock Technical Analysis
| PLX Stock | USD 2.83 0.04 1.43% |
As of the 15th of March 2026, Protalix Biotherapeutics is valued at 2.83 per share. Indicator levels currently stand at Coefficient Of Variation of 495.74, risk adjusted performance of 0.1684, and Semi Deviation of 2.46. Historical price dispersion and volume trends are incorporated into the evaluation. Values are analyzed in relation to historical volatility thresholds.
Protalix Biotherapeutics Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Protalix, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to ProtalixProtalix Biotherapeutics' Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 11.0 | Buy | 1 | Odds |
Current and historical analyst recommendations for Protalix Biotherapeutics are summarized from research sources. The summary includes average consensus context. Research analysts covering Protalix use a range of valuation methodologies - including DCF, comparable company analysis, and sum-of-the-parts - to derive price targets for Protalix Biotherapeutics. Divergences in these targets reflect differences in assumptions about growth, margins, and discount.
Quarterly Earnings Growth -0.01 | Earnings Share 0.08 | Revenue Per Share | Quarterly Revenue Growth -0.01 | Return On Assets |
Understanding Protalix Biotherapeutics includes distinguishing between market value and book value, where book value reflects Protalix's accounting equity. Protalix Biotherapeutics' market capitalization is 227.59 M. With a P/B ratio of 4.3, the market values Protalix Biotherapeutics well above its book equity. Enterprise value stands at 206.4 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
It is useful to distinguish Protalix Biotherapeutics' value from its trading price, which are computed with different methods. For Protalix Biotherapeutics, key inputs include a P/B ratio of 4.3, a profit margin of 8.72%, ROE of 12.64%, and revenue of 53.4 M. By contrast, market price reflects the level where buyers and sellers transact.
What if' Analysis
Running a what-if backtest on Protalix Biotherapeutics gives investors a practical way to test how changes in horizon, position size, or market timing might have affected the result. Used properly, this review helps investors decide whether Protalix Biotherapeutics' historical reward profile was stable enough to support the current thesis.
| 12/15/2025 |
| 03/15/2026 |
An initial 0.00 allocation to Protalix Biotherapeutics on December 15, 2025 held through today would generate 0.00 in cumulative gains. Overall, this is a 0.0% total return in Protalix Biotherapeutics in aggregate over 90 days. Protalix Biotherapeutics is often compared with Sellas Life, Coherus BioSciences, Invivyd, Protara Therapeutics, Codexis, OmniAb, and NeOnc Technologies based on sector and business overlap. The comparison helps frame competitive context. Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombi... More
Protalix Biotherapeutics Momentum Range Indicators Summary
This section highlights upside and downside signals that contextualize Protalix Biotherapeutics price behavior. This view helps summarize momentum conditions without implying direction.
| Downside Deviation | 3.12 | |||
| Information Ratio | 0.2103 | |||
| Maximum Drawdown | 19.64 | |||
| Value At Risk | -4.32 | |||
| Potential Upside | 9.92 |
Protalix Biotherapeutics Volatility and Risk Indicators Summary
This section presents risk metrics that describe Protalix Biotherapeutics' historical price variability. The measures summarize variability without implying direction.| Risk Adjusted Performance | 0.1684 | |||
| Jensen Alpha | 0.8523 | |||
| Total Risk Alpha | 1.04 | |||
| Sortino Ratio | 0.2737 | |||
| Treynor Ratio | 0.8198 |
The mean reversion effect in Protalix Biotherapeutics is stronger when the initial deviation was driven by sentiment rather than fundamental change. Identifying the root cause of Protalix Biotherapeutics' price dislocation is essential before acting.
Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1684 | |||
| Market Risk Adjusted Performance | 0.8298 | |||
| Mean Deviation | 2.99 | |||
| Semi Deviation | 2.46 | |||
| Downside Deviation | 3.12 | |||
| Coefficient Of Variation | 495.74 | |||
| Standard Deviation | 4.06 | |||
| Variance | 16.45 | |||
| Information Ratio | 0.2103 | |||
| Jensen Alpha | 0.8523 | |||
| Total Risk Alpha | 1.04 | |||
| Sortino Ratio | 0.2737 | |||
| Treynor Ratio | 0.8198 | |||
| Maximum Drawdown | 19.64 | |||
| Value At Risk | -4.32 | |||
| Potential Upside | 9.92 | |||
| Downside Variance | 9.71 | |||
| Semi Variance | 6.03 | |||
| Expected Short fall | -3.57 | |||
| Skewness | 1.03 | |||
| Kurtosis | 1.43 |
Protalix Biotherapeutics Backtested Returns
Protalix Biotherapeutics demonstrates a relatively elevated risk exposure under current market conditions. It has a Sharpe Ratio of 0.21, evidencing risk-calibrated returns. We identified twenty-nine technical indicators influencing the company's volatility profile. Please assess metrics such as risk-adjusted performance of 0.1684, semi deviation of 2.46, and Coefficient Of Variation of 495.74 to confirm statistical stability. On a scale of 0 to 100, Protalix Biotherapeutics holds a performance score of 16. The firm maintains a market beta of 0.99, which means possible diversification benefits within a given portfolio. Protalix Biotherapeutics returns are very sensitive to returns on the market. As the market goes up or down, Protalix Biotherapeutics is expected to follow. Please verify Protalix Biotherapeutics' the relationship between the accumulation distribution and price action indicator, to make a quick decision on whether Protalix Biotherapeutics' current trending patterns will revert.
Auto-correlation | 0.19 |
Very weak predictability
The autocorrelation profile for Protalix Biotherapeutics registers very weak predictability between the two measured intervals. When lagged price patterns show consistency, they can serve as a partial input for modeling Protalix Biotherapeutics's near-term price behavior. A serial correlation of 0.19 indicates that over 19.0% of current Protalix Biotherapeutics price fluctuations can be explained by its historical price movements.
| Correlation Coefficient | 0.19 | |
| Spearman Rank Test | 0.14 | |
| Residual Average | 0.0 | |
| Price Variance | 0.05 |
Technical analysis for Protalix Biotherapeutics examines price and volume behavior across market regimes. The view references moving averages, RSI, regressions, and chart pattern signals.
Technical Analysis
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Protalix Biotherapeutics volatility. High ATR values indicate high volatility, and low values indicate low volatility.
Technical Analysis Methodology & Indicators
Technical analysis of Protalix Biotherapeutics evaluates price structure, momentum, and volatility clustering. Range expansion increases sensitivity to execution and spread conditions. Protalix Biotherapeutics has a market cap of 227.59 M, ROE of 12.64%.
Unless otherwise specified, data for Protalix Biotherapeutics is compiled from periodic company reporting and market reference feeds and standardized for comparability. Updates may occur throughout the day.
This content is curated and reviewed by:
Ellen Johnson - Member of Macroaxis Editorial BoardProtalix Biotherapeutics Technical Indicators
A technical review of Protalix Biotherapeutics can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. The stronger process confirms one signal with others instead of reacting to one pattern in isolation.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1684 | |||
| Market Risk Adjusted Performance | 0.8298 | |||
| Mean Deviation | 2.99 | |||
| Semi Deviation | 2.46 | |||
| Downside Deviation | 3.12 | |||
| Coefficient Of Variation | 495.74 | |||
| Standard Deviation | 4.06 | |||
| Variance | 16.45 | |||
| Information Ratio | 0.2103 | |||
| Jensen Alpha | 0.8523 | |||
| Total Risk Alpha | 1.04 | |||
| Sortino Ratio | 0.2737 | |||
| Treynor Ratio | 0.8198 | |||
| Maximum Drawdown | 19.64 | |||
| Value At Risk | -4.32 | |||
| Potential Upside | 9.92 | |||
| Downside Variance | 9.71 | |||
| Semi Variance | 6.03 | |||
| Expected Short fall | -3.57 | |||
| Skewness | 1.03 | |||
| Kurtosis | 1.43 |
March 15, 2026 Daily Trend Indicators
A technical review of Protalix Biotherapeutics can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. The stronger process confirms one signal with others instead of reacting to one pattern in isolation.
| Accumulation Distribution | 0.03 | ||
| Daily Balance Of Power | 0.40 | ||
| Rate Of Daily Change | 1.01 | ||
| Day Median Price | 2.83 | ||
| Day Typical Price | 2.83 | ||
| Price Action Indicator | 0.02 | ||
| Market Facilitation Index | 0.10 |
Popular Tools for Protalix Stock analysis
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |